In vivo genome editing of ANGPTL3: a therapy for atherosclerosis?

被引：10
|
作者：
Rhee, June-Wha [1 ,2 ]
Wu, Joseph C. [1 ,2 ,3 ]
机构：
[1] Stanford Cardiovasc Inst, Stanford, CA 94305 USA
[2] Stanford Univ, Sch Med, Dept Med, Div Cardiovasc Med, Stanford, CA 94305 USA
[3] Stanford Univ, Sch Med, Dept Radiol, Stanford, CA 94305 USA
来源：
NATURE REVIEWS CARDIOLOGY | 2018年 / 15卷 / 05期
关键词：
DISEASE; DNA;
D O I：
10.1038/nrcardio.2018.38
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Hyperlipidaemia is an important risk factor for coronary artery disease. Chadwick and colleagues report significantly reduced blood lipid levels following CRISPR-based in vivo genome editing in mice to introduce loss-of-function mutations in Angptl3, encoding a lipoprotein lipase inhibitor. Treatment was effective in both wild-type and Ldlr(-/-) mice and had a similar effect to that of Pcsk9-targeted genome editing, without causing off-target mutations.
引用
收藏
页码：259 / 260
页数：2
相关论文
共 50 条
  • [1] In vivo genome editing of ANGPTL3: a therapy for atherosclerosis?
    June-Wha Rhee
    Joseph C. Wu
    Nature Reviews Cardiology, 2018, 15 : 259 - 260
  • [2] ANGPTL3: a therapeutic target for atherosclerosis
    Gregory B. Lim
    Nature Reviews Cardiology, 2017, 14 : 381 - 381
  • [3] In Vivo CRISPR Base Editing of Angptl3 via Lipid Nanoparticle Delivery
    Khirallah, Jennifer
    Bloomer, Hanan
    Newby, Gregory
    Rhee, Hyunjoon
    Eimbinder, Maximilian
    Huang, Changfeng
    Li, Yamin
    Chen, Zheng-Yi
    Liu, David
    Xu, Qiaobing
    MOLECULAR THERAPY, 2023, 31 (04) : 247 - 248
  • [4] ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis
    Mohamed, Farzahna
    Mansfield, Brett S.
    Raal, Frederick J.
    CURRENT ATHEROSCLEROSIS REPORTS, 2022, 24 (12) : 959 - 967
  • [5] Dyslipidaemia ANGPTL3: a therapeutic target for atherosclerosis
    Lim, Gregory B.
    NATURE REVIEWS CARDIOLOGY, 2017, 14 (07) : 381 - 381
  • [6] ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis
    Farzahna Mohamed
    Brett S. Mansfield
    Frederick J. Raal
    Current Atherosclerosis Reports, 2022, 24 : 959 - 967
  • [7] In vivo base editing of Angptl3 via lipid nanoparticles to treat cardiovascular disease
    Khirallah, Jennifer
    Bloomer, Hanan
    Wich, Douglas
    Huang, Changfeng
    Workman, J. Noah
    Li, Yamin
    Newby, Gregory A.
    Liu, David R.
    Xu, Qiaobing
    MOLECULAR THERAPY NUCLEIC ACIDS, 2025, 36 (02):
  • [8] An in vivo CRISPR base editing therapy to inactivate the ANGPTL3 gene: nomination of a development candidate for VERVE-201
    Khera, A.
    Lee, R.
    Rohde, E.
    Jayaram, H.
    Kathiresan, S.
    Bellinger, A.
    EUROPEAN HEART JOURNAL, 2022, 43 : 3087 - 3087
  • [9] Reduced Blood Lipid Levels With In Vivo CRISPR-Cas9 Base Editing of ANGPTL3
    Chadwick, Alexandra C.
    Evitt, Niklaus H.
    Lv, Wenjian
    Musunuru, Kiran
    CIRCULATION, 2018, 137 (09) : 975 - 977
  • [10] Gene Editing Targeting Angptl3 By SlugCas9 Ameliorates Lipid Metabolism And Atherosclerosis In Familial Hypercholesterolemia
    Yin, Ye
    Li, Zhixing
    Xu, Hong
    Shen, Qian
    Ji, Baowei
    Wang, Yongming
    Ge, Junbo
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2023, 43
12345